For help on how to get the results you want, see our search tips.
1718 results
Categories
Human Remove Human filter
-
List item
Human medicine European public assessment report (EPAR): Pluvicto
lutetium (177Lu) vipivotide tetraxetan, Prostatic Neoplasms, Castration-Resistant
Date of authorisation: 09/12/2022,
, Revision: 2, Authorised, Last updated: 19/04/2023
-
List item
Human medicine European public assessment report (EPAR): Livmarli (updated)
Maralixibat chloride, Alagille Syndrome
Date of authorisation: 09/12/2022,, 
, 
, Revision: 1, Authorised, Last updated: 25/05/2023
-
List item
Human medicine European public assessment report (EPAR): Qdenga
Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated, Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated, Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated, Dengue virus, serotype 2, live, attenuated, Dengue
Date of authorisation: 05/12/2022,, Authorised, Last updated: 12/04/2023
-
List item
Human medicine European public assessment report (EPAR): Mycapssa
Octreotide acetate, Acromegaly
Date of authorisation: 02/12/2022,, Authorised, Last updated: 22/12/2022
-
List item
Human medicine European public assessment report (EPAR): Teriparatide Sun
teriparatide, Osteoporosis; Osteoporosis, Postmenopausal
Date of authorisation: 18/11/2022, Authorised, Last updated: 12/12/2022 -
List item
Human medicine European public assessment report (EPAR): Enjaymo
sutimlimab, Hemolysis; Anemia, Hemolytic, Autoimmune
Date of authorisation: 15/11/2022,, , Revision: 2, Authorised, Last updated: 13/04/2023
-
List item
Human medicine European public assessment report (EPAR): VidPrevtyn Beta
SARS-CoV-2 prefusion Spike delta TM protein, recombinant (B.1.351 strain), COVID-19 virus infection
Date of authorisation: 10/11/2022,, Authorised, Last updated: 30/11/2022
-
List item
Human medicine European public assessment report (EPAR): Ximluci
ranibizumab, Wet Macular Degeneration; Macular Edema; Diabetic Retinopathy; Diabetes Complications
Date of authorisation: 09/11/2022,, 
, Authorised, Last updated: 29/11/2022
-
List item
Human medicine European public assessment report (EPAR): Pyrukynd
mitapivat sulfate, Genetic Diseases, Inborn; Anemia, Hemolytic
Date of authorisation: 09/11/2022,, , Authorised, Last updated: 05/12/2022
-
List item
Human medicine European public assessment report (EPAR): Teriflunomide Accord
Teriflunomide, Multiple Sclerosis, Relapsing-Remitting
Date of authorisation: 09/11/2022,
, Authorised, Last updated: 14/11/2022
-
List item
Human medicine European public assessment report (EPAR): Teriflunomide Mylan
Teriflunomide, Multiple Sclerosis, Relapsing-Remitting
Date of authorisation: 09/11/2022,, Revision: 1, Authorised, Last updated: 16/01/2023
-
List item
Human medicine European public assessment report (EPAR): Sorafenib Accord
Sorafenib tosilate, Carcinoma, Hepatocellular; Carcinoma, Renal Cell
Date of authorisation: 09/11/2022,, Authorised, Last updated: 25/11/2022
-
List item
Human medicine European public assessment report (EPAR): Livtencity
Maribavir, Cytomegalovirus Infections
Date of authorisation: 09/11/2022,, , Revision: 3, Authorised, Last updated: 17/03/2023
-
List item
Human medicine European public assessment report (EPAR): Melatonin Neurim
melatonin, Sleep Initiation and Maintenance Disorders
Date of authorisation: 07/11/2022, Authorised, Last updated: 25/11/2022 -
List item
Human medicine European public assessment report (EPAR): Beyfortus
nirsevimab,
Date of authorisation: 31/10/2022,, Revision: 2, Authorised, Last updated: 28/04/2023
-
List item
Human medicine European public assessment report (EPAR): Thalidomide Lipomed
Thalidomide, Multiple Myeloma
Date of authorisation: 19/09/2022, Authorised, Last updated: 20/10/2022 -
List item
Human medicine European public assessment report (EPAR): Tezspire
tezepelumab, Asthma
Date of authorisation: 19/09/2022,, Revision: 3, Authorised, Last updated: 19/04/2023
-
List item
Human medicine European public assessment report (EPAR): Vabysmo
Faricimab, Wet Macular Degeneration; Macular Edema; Diabetes Complications
Date of authorisation: 15/09/2022,, Authorised, Last updated: 13/10/2022
-
List item
Human medicine European public assessment report (EPAR): Amvuttra
vutrisiran sodium, Amyloid Neuropathies, Familial
Date of authorisation: 15/09/2022,, , Revision: 1, Authorised, Last updated: 10/01/2023
-
List item
Human medicine European public assessment report (EPAR): Lupkynis
Voclosporin, Lupus Nephritis
Date of authorisation: 15/09/2022,, Revision: 1, Authorised, Last updated: 07/02/2023
-
List item
Human medicine European public assessment report (EPAR): Nulibry
fosdenopterin hydrobromide dihydrate, Metal Metabolism, Inborn Errors
Date of authorisation: 15/09/2022,, , Revision: 1, Authorised, Last updated: 20/02/2023
-
List item
Human medicine European public assessment report (EPAR): Lutetium (177Lu) chloride Billev (previously Illuzyce)
lutetium (177Lu) chloride, Radionuclide Imaging
Date of authorisation: 15/09/2022, Revision: 1, Authorised, Last updated: 08/12/2022 -
List item
Human medicine European public assessment report (EPAR): Opdualag
nivolumab, Relatlimab, Melanoma
Date of authorisation: 15/09/2022,, Authorised, Last updated: 17/10/2022
-
List item
Human medicine European public assessment report (EPAR): Celdoxome pegylated liposomal
doxorubicin hydrochloride, Breast Neoplasms; Ovarian Neoplasms; Multiple Myeloma; Sarcoma, Kaposi
Date of authorisation: 15/09/2022, Revision: 1, Authorised, Last updated: 13/04/2023 -
List item
Human medicine European public assessment report (EPAR): Mounjaro (updated)
Tirzepatide, Diabetes Mellitus, Type 2
Date of authorisation: 15/09/2022, Revision: 2, Authorised, Last updated: 12/05/2023